FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2799682570> ?p ?o ?g. }

• W2799682570 endingPage "113" @default.
• W2799682570 startingPage "104" @default.
• W2799682570 abstract "Standard treatment options for patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC) are associated with limited efficacy and some toxicity. Recently, immunotherapy with antibodies that inhibit the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) interaction has emerged as a new treatment option. This manuscript reviews early-phase and late-phase trials of immunotherapy in advanced GC/GEJC.Searches for studies of immunotherapy in GC/GEJC were performed using PubMed, ClinicalTrials.gov, and abstract databases for select annual congresses. Findings were interpreted based on expert opinion.Monotherapy with anti-PD-1/PD-L1 antibodies, including pembrolizumab, nivolumab, avelumab, durvalumab, and atezolizumab, has shown interesting objective response rates (ORRs; 7-26%) across varying GC/GEJC populations, with ORRs potentially higher in PD-L1 + vs PD-L1 - tumors. Safety profiles compare favorably with chemotherapy, with grade ≥3 treatment-related adverse events occurring in 5-17%. Based on a large phase 2 study, pembrolizumab was approved in the United States for third-line treatment of patients with PD-L1 + GC/GEJC. In a phase 3 trial, third-line or later nivolumab increased overall survival vs placebo in an Asian population, leading to regulatory approval in Japan, although other completed phase 3 trials did not show superiority for pembrolizumab or avelumab monotherapy vs chemotherapy. Other trials in advanced GC/GEJC are assessing various anti-PD-1/PD-L1-based strategies, including administration in first-line and later-line settings and as combination (with chemotherapy or agents targeting other immune checkpoint proteins, eg, CTLA-4, LAG-3, and IDO) or switch-maintenance regimens.Anti-PD-1/PD-L1 antibodies have shown encouraging clinical activity in advanced GC/GEJC. Results from ongoing phase 3 trials are needed to further evaluate the potential roles of these agents within the continuum of care." @default.
• W2799682570 created "2018-05-17" @default.
• W2799682570 creator A5010090426 @default.
• W2799682570 creator A5024180743 @default.
• W2799682570 creator A5038131926 @default.
• W2799682570 creator A5039383124 @default.
• W2799682570 creator A5044064524 @default.
• W2799682570 creator A5055342345 @default.
• W2799682570 creator A5063821551 @default.
• W2799682570 creator A5078338048 @default.
• W2799682570 creator A5091587460 @default.
• W2799682570 date "2018-05-01" @default.
• W2799682570 modified "2023-10-16" @default.
• W2799682570 title "Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives" @default.
• W2799682570 cites W1518184777 @default.
• W2799682570 cites W1605630196 @default.
• W2799682570 cites W1940241680 @default.
• W2799682570 cites W1969765578 @default.
• W2799682570 cites W1984545852 @default.
• W2799682570 cites W2004630197 @default.
• W2799682570 cites W2016983859 @default.
• W2799682570 cites W2046972425 @default.
• W2799682570 cites W2059755429 @default.
• W2799682570 cites W2066671159 @default.
• W2799682570 cites W2068411507 @default.
• W2799682570 cites W2071069178 @default.
• W2799682570 cites W2074134583 @default.
• W2799682570 cites W2085125246 @default.
• W2799682570 cites W2096322385 @default.
• W2799682570 cites W2100439220 @default.
• W2799682570 cites W2104759721 @default.
• W2799682570 cites W2111237964 @default.
• W2799682570 cites W2117355364 @default.
• W2799682570 cites W2117692326 @default.
• W2799682570 cites W2120390507 @default.
• W2799682570 cites W2122866527 @default.
• W2799682570 cites W2124427232 @default.
• W2799682570 cites W2126547130 @default.
• W2799682570 cites W2131227532 @default.
• W2799682570 cites W2135947389 @default.
• W2799682570 cites W2150024391 @default.
• W2799682570 cites W2152362765 @default.
• W2799682570 cites W2156253417 @default.
• W2799682570 cites W2165411051 @default.
• W2799682570 cites W2167191456 @default.
• W2799682570 cites W2263759961 @default.
• W2799682570 cites W2293605493 @default.
• W2799682570 cites W2300582328 @default.
• W2799682570 cites W2314158075 @default.
• W2799682570 cites W2328871448 @default.
• W2799682570 cites W2342599605 @default.
• W2799682570 cites W2342925107 @default.
• W2799682570 cites W2347070489 @default.
• W2799682570 cites W2400719370 @default.
• W2799682570 cites W2407152983 @default.
• W2799682570 cites W2507974650 @default.
• W2799682570 cites W2522354642 @default.
• W2799682570 cites W2558269388 @default.
• W2799682570 cites W2563490717 @default.
• W2799682570 cites W2567116115 @default.
• W2799682570 cites W2568542640 @default.
• W2799682570 cites W2570401594 @default.
• W2799682570 cites W2585754738 @default.
• W2799682570 cites W2610126086 @default.
• W2799682570 cites W2725487442 @default.
• W2799682570 cites W2736166064 @default.
• W2799682570 cites W2736457196 @default.
• W2799682570 cites W2747774814 @default.
• W2799682570 cites W2758552192 @default.
• W2799682570 cites W2763064222 @default.
• W2799682570 cites W2783897381 @default.
• W2799682570 cites W4211007657 @default.
• W2799682570 cites W4242151806 @default.
• W2799682570 cites W951317561 @default.
• W2799682570 doi "https://doi.org/10.1016/j.ctrv.2018.04.004" @default.
• W2799682570 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29730461" @default.
• W2799682570 hasPublicationYear "2018" @default.
• W2799682570 type Work @default.
• W2799682570 sameAs 2799682570 @default.
• W2799682570 citedByCount "68" @default.
• W2799682570 countsByYear W27996825702018 @default.
• W2799682570 countsByYear W27996825702019 @default.
• W2799682570 countsByYear W27996825702020 @default.
• W2799682570 countsByYear W27996825702021 @default.
• W2799682570 countsByYear W27996825702022 @default.
• W2799682570 countsByYear W27996825702023 @default.
• W2799682570 crossrefType "journal-article" @default.
• W2799682570 hasAuthorship W2799682570A5010090426 @default.
• W2799682570 hasAuthorship W2799682570A5024180743 @default.
• W2799682570 hasAuthorship W2799682570A5038131926 @default.
• W2799682570 hasAuthorship W2799682570A5039383124 @default.
• W2799682570 hasAuthorship W2799682570A5044064524 @default.
• W2799682570 hasAuthorship W2799682570A5055342345 @default.
• W2799682570 hasAuthorship W2799682570A5063821551 @default.
• W2799682570 hasAuthorship W2799682570A5078338048 @default.
• W2799682570 hasAuthorship W2799682570A5091587460 @default.
• W2799682570 hasBestOaLocation W27996825701 @default.
• W2799682570 hasConcept C121608353 @default.

• next